Complete Wegovy vs Mounjaro Dosage Comparison for Private Patients
Private Prescription Access: Wegovy vs Mounjaro Dosage Chart Without NHS Delays
The wegovy vs mounjaro dosage chart comparison becomes particularly relevant for private patients seeking immediate access to weight management treatments. NHS specialist weight management services typically require 6+ month waiting periods following GP referrals, during which time patients must demonstrate unsuccessful conventional weight loss attempts. Private prescription services eliminate these barriers entirely, allowing qualified prescribers to assess your suitability for either treatment based on clinical criteria rather than postcode lottery availability.
EverydayMeds operates as a GPhC-registered pharmacy (#9012878) providing both treatments through legitimate private prescription pathways. Your chosen prescriber reviews the complete wegovy vs mounjaro dosage chart alongside your individual health profile, ensuring the selected treatment aligns with your lifestyle, medical history, and weight management goals. This personalised approach contrasts sharply with the standardised NHS protocols that may limit treatment options based on local formulary restrictions.
Wegovy vs Mounjaro Dosage Chart: Complete Pricing Structure
Understanding the wegovy vs mounjaro dosage chart extends beyond clinical dosing to include transparent private prescription costs. Wegovy follows a 20-week escalation schedule with single pen prices ranging from £79.99 (0.25mg starter) to £209.99 (2.4mg maintenance). New customers apply discount code FIRST40 at checkout, while returning patients use DOSE25 to reach these final pricing levels. Bundle options like the Intro Trio (0.25mg, 0.5mg, 1mg) cost £299.99, providing three months of step-up dosing with Reliable Supply continuity.
Mounjaro pricing follows a similar structure though with different dose increments reflecting its tirzepatide formulation. Both treatments require identical private prescription processes, with prescriber fees included in the stated pen prices. The wegovy vs mounjaro dosage chart comparison reveals that total treatment costs depend more on individual tolerance and efficacy rather than fundamental pricing differences between the two prescription-only medicines.
Clinical Evidence Supporting Wegovy vs Mounjaro Dosage Chart Protocols
The wegovy vs mounjaro dosage chart protocols derive from extensive clinical trial programmes demonstrating optimal tolerance and efficacy profiles. Wegovy's escalation schedule was established through the STEP trial series, with STEP 1 showing approximately 15% average weight loss at 68 weeks when patients followed the prescribed dosing alongside reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The gradual dose increases minimise gastrointestinal side effects while maximising treatment adherence.
Mounjaro's dosing schedule reflects its dual GIP/GLP-1 receptor agonist mechanism, with clinical trials suggesting the stepped approach optimises both glucose regulation and weight management outcomes. Neither wegovy vs mounjaro dosage chart should be compared directly in terms of weight loss percentages, as trial populations, endpoints, and methodologies differed significantly. Both treatments are subject to MHRA additional monitoring, reflecting their relatively recent market authorisation for weight management indications.
Wegovy Mechanism: GLP-1 Receptor Agonist Function
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of natural incretin hormones released after eating. This mechanism reduces appetite by acting on brain appetite centres, particularly in the hypothalamus where hunger and satiety signals are processed. Patients typically experience increased feelings of fullness after smaller meal portions, alongside reduced food cravings throughout the day. The once-weekly injection schedule maintains consistent therapeutic levels, supporting sustainable appetite regulation rather than rapid fluctuations. Clinical studies indicate that Wegovy may slow gastric emptying, contributing to prolonged satiety sensations that support adherence to reduced-calorie dietary patterns. This biological approach to weight management explains why the prescription-only medicine must be combined with lifestyle modifications for optimal efficacy.
Private Prescription Ordering Process: Wegovy vs Mounjaro Dosage Chart Access
Accessing either treatment through EverydayMeds follows an identical streamlined process designed for busy professionals seeking efficient healthcare solutions. The 3-minute online clinical assessment captures essential medical history, current medications, weight management goals, and previous treatment experiences relevant to the wegovy vs mounjaro dosage chart evaluation. Qualified prescribers review your submission within standard 3 working days (or 24 hours with express service), determining treatment suitability based on MHRA-approved licensing criteria. Once approved, your chosen treatment ships via next-day delivery using temperature-controlled cold-chain logistics, ensuring medication integrity throughout transit. This entire process bypasses traditional GP appointments, specialist referrals, and NHS waiting lists that can delay treatment initiation by 6+ months. GPhC registration (#9012878) ensures pharmaceutical quality standards equivalent to NHS hospital pharmacy services.
Storage and Practical Considerations: Wegovy vs Mounjaro Dosage Chart Implementation
The wegovy vs mounjaro dosage chart comparison includes important practical differences affecting daily treatment management. Wegovy pens require refrigeration at 2-8°C before first use but tolerate room temperature storage for up to 6 weeks once removed from the fridge, providing significant travel flexibility for business professionals or frequent travellers. Each FlexTouch pen delivers exactly four doses at the prescribed strength, with clear dosing windows indicating remaining medication. The mandatory dose escalation schedule cannot be accelerated regardless of initial tolerance, as clinical trials demonstrate that premature dose increases significantly elevate side effect risks. Patients must complete the full 16-week escalation before reaching the 2.4mg maintenance dose, requiring commitment to the structured dosing protocol. Most private patients appreciate the predictable weekly injection schedule that integrates seamlessly with professional routines, unlike daily medications requiring multiple dosing throughout busy workdays.
Private vs NHS Access: Wegovy vs Mounjaro Dosage Chart Availability Timeline
The wegovy vs mounjaro dosage chart becomes immediately relevant for private patients, whereas NHS access involves complex eligibility criteria and extensive waiting periods. NHS specialist weight management services typically require BMI documentation over 6+ months, evidence of failed conventional approaches, and postcode-dependent service availability that varies dramatically across UK regions. Many NHS trusts maintain closed referral lists or impose additional restrictions beyond NICE TA875 recommendations, effectively limiting access despite clinical eligibility.
Private prescription eliminates these systemic barriers while maintaining identical clinical safety standards and prescriber qualifications. Your chosen treatment from the wegovy vs mounjaro dosage chart begins within days rather than months, allowing weight management progress during the time you would otherwise spend on NHS waiting lists. This temporal advantage proves particularly valuable for patients with work commitments, family obligations, or health conditions where delayed treatment intervention may compromise long-term outcomes.
Treatment Selection and Ongoing Support: Wegovy vs Mounjaro Dosage Chart Optimisation
EverydayMeds prescribers provide comprehensive guidance throughout your wegovy vs mounjaro dosage chart journey, ensuring treatment optimisation based on individual response patterns and lifestyle factors. Regular clinical reviews monitor progress, side effect management, and dose escalation timing according to established protocols. Should your initially selected treatment prove unsuitable due to tolerance issues or inadequate response, prescribers can facilitate transition to the alternative option without requiring fresh GP referrals or specialist appointments. This flexibility proves particularly valuable during the initial months when treatment response patterns become apparent. Bundle purchasing options like the Progress Trio (0.5mg, 1mg, 1.7mg) for £369.99 ensure treatment continuity while your prescriber monitors clinical response. Returning customers benefit from DOSE25 discount code applied at checkout, recognising the long-term commitment required for sustainable weight management outcomes. Explore our complete Wegovy range to discuss treatment options with qualified prescribers who understand the nuances of private prescription weight management.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
